Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer

Payton Solk, Kara Gavin, Jason Fanning, Whitney Welch, Gillian Lloyd, Alison Cottrell, Anne Nielsen, Cesar A. Santa Maria, William Gradishar, Seema A. Khan, Swati Kulkarni, Juned Siddique, Siobhan M. Phillips*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Purpose: Ecological momentary assessment (EMA) may help us better understand biopsychosocial determinants and outcomes of physical activity during chemotherapy, but may be burdensome for patients. The purpose of this study was to determine the feasibility and acceptability of using EMA to assess activity, symptoms, and motivation among early-stage breast cancer patients undergoing chemotherapy. Methods: Women were instructed to wear an accelerometer 24/7 (hip during day and wrist overnight). Text message prompts were sent 4 times/day concerning patient-reported symptoms and motivational factors for 10 consecutive days (3 days pre-, day of, and 6 days post-chemotherapy dose). These measures occurred at the beginning, middle, and end of a full course of chemotherapy. At study conclusion, participants reported on perceived study acceptability, burden, and reactivity. Results: Of the 75 women who consented to participate, 63 (84%) completed all 3 assessment time points. Participants responded to 86% of total text prompts and had valid accelerometer data on 82% of study days. Compliance was similar across all time points. The majority (78%) rated their study experience as positive; 100% were confident in their ability to use study technology. Reactivity varied with 27% indicating answering symptom questions did not affect how they felt and 44% and 68% indicated answering questions and wearing the accelerometer, respectively, made them want to increase activity. Conclusions: Findings indicate EMA methods are feasible for breast cancer patients undergoing chemotherapy. EMA may help us better understand the biopsychosocial processes underlying breast cancer patients’ activity in the context of daily life.

Original languageEnglish (US)
Pages (from-to)3333-3346
Number of pages14
JournalQuality of Life Research
Volume28
Issue number12
DOIs
StatePublished - Dec 1 2019

Fingerprint

Breast Neoplasms
Drug Therapy
Text Messaging
Aptitude
Wrist
Compliance
Hip
Motivation
Patient Reported Outcome Measures
Exercise
Technology
Ecological Momentary Assessment

Keywords

  • Breast cancer
  • Chemotherapy
  • Patient-reported outcomes
  • Physical activity
  • mHealth

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

@article{dc1c644362dc4e16a6525c4cfbbbb3d7,
title = "Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer",
abstract = "Purpose: Ecological momentary assessment (EMA) may help us better understand biopsychosocial determinants and outcomes of physical activity during chemotherapy, but may be burdensome for patients. The purpose of this study was to determine the feasibility and acceptability of using EMA to assess activity, symptoms, and motivation among early-stage breast cancer patients undergoing chemotherapy. Methods: Women were instructed to wear an accelerometer 24/7 (hip during day and wrist overnight). Text message prompts were sent 4 times/day concerning patient-reported symptoms and motivational factors for 10 consecutive days (3 days pre-, day of, and 6 days post-chemotherapy dose). These measures occurred at the beginning, middle, and end of a full course of chemotherapy. At study conclusion, participants reported on perceived study acceptability, burden, and reactivity. Results: Of the 75 women who consented to participate, 63 (84{\%}) completed all 3 assessment time points. Participants responded to 86{\%} of total text prompts and had valid accelerometer data on 82{\%} of study days. Compliance was similar across all time points. The majority (78{\%}) rated their study experience as positive; 100{\%} were confident in their ability to use study technology. Reactivity varied with 27{\%} indicating answering symptom questions did not affect how they felt and 44{\%} and 68{\%} indicated answering questions and wearing the accelerometer, respectively, made them want to increase activity. Conclusions: Findings indicate EMA methods are feasible for breast cancer patients undergoing chemotherapy. EMA may help us better understand the biopsychosocial processes underlying breast cancer patients’ activity in the context of daily life.",
keywords = "Breast cancer, Chemotherapy, Patient-reported outcomes, Physical activity, mHealth",
author = "Payton Solk and Kara Gavin and Jason Fanning and Whitney Welch and Gillian Lloyd and Alison Cottrell and Anne Nielsen and {Santa Maria}, {Cesar A.} and William Gradishar and Khan, {Seema A.} and Swati Kulkarni and Juned Siddique and Phillips, {Siobhan M.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1007/s11136-019-02278-7",
language = "English (US)",
volume = "28",
pages = "3333--3346",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "12",

}

Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer. / Solk, Payton; Gavin, Kara; Fanning, Jason; Welch, Whitney; Lloyd, Gillian; Cottrell, Alison; Nielsen, Anne; Santa Maria, Cesar A.; Gradishar, William; Khan, Seema A.; Kulkarni, Swati; Siddique, Juned; Phillips, Siobhan M.

In: Quality of Life Research, Vol. 28, No. 12, 01.12.2019, p. 3333-3346.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer

AU - Solk, Payton

AU - Gavin, Kara

AU - Fanning, Jason

AU - Welch, Whitney

AU - Lloyd, Gillian

AU - Cottrell, Alison

AU - Nielsen, Anne

AU - Santa Maria, Cesar A.

AU - Gradishar, William

AU - Khan, Seema A.

AU - Kulkarni, Swati

AU - Siddique, Juned

AU - Phillips, Siobhan M.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Purpose: Ecological momentary assessment (EMA) may help us better understand biopsychosocial determinants and outcomes of physical activity during chemotherapy, but may be burdensome for patients. The purpose of this study was to determine the feasibility and acceptability of using EMA to assess activity, symptoms, and motivation among early-stage breast cancer patients undergoing chemotherapy. Methods: Women were instructed to wear an accelerometer 24/7 (hip during day and wrist overnight). Text message prompts were sent 4 times/day concerning patient-reported symptoms and motivational factors for 10 consecutive days (3 days pre-, day of, and 6 days post-chemotherapy dose). These measures occurred at the beginning, middle, and end of a full course of chemotherapy. At study conclusion, participants reported on perceived study acceptability, burden, and reactivity. Results: Of the 75 women who consented to participate, 63 (84%) completed all 3 assessment time points. Participants responded to 86% of total text prompts and had valid accelerometer data on 82% of study days. Compliance was similar across all time points. The majority (78%) rated their study experience as positive; 100% were confident in their ability to use study technology. Reactivity varied with 27% indicating answering symptom questions did not affect how they felt and 44% and 68% indicated answering questions and wearing the accelerometer, respectively, made them want to increase activity. Conclusions: Findings indicate EMA methods are feasible for breast cancer patients undergoing chemotherapy. EMA may help us better understand the biopsychosocial processes underlying breast cancer patients’ activity in the context of daily life.

AB - Purpose: Ecological momentary assessment (EMA) may help us better understand biopsychosocial determinants and outcomes of physical activity during chemotherapy, but may be burdensome for patients. The purpose of this study was to determine the feasibility and acceptability of using EMA to assess activity, symptoms, and motivation among early-stage breast cancer patients undergoing chemotherapy. Methods: Women were instructed to wear an accelerometer 24/7 (hip during day and wrist overnight). Text message prompts were sent 4 times/day concerning patient-reported symptoms and motivational factors for 10 consecutive days (3 days pre-, day of, and 6 days post-chemotherapy dose). These measures occurred at the beginning, middle, and end of a full course of chemotherapy. At study conclusion, participants reported on perceived study acceptability, burden, and reactivity. Results: Of the 75 women who consented to participate, 63 (84%) completed all 3 assessment time points. Participants responded to 86% of total text prompts and had valid accelerometer data on 82% of study days. Compliance was similar across all time points. The majority (78%) rated their study experience as positive; 100% were confident in their ability to use study technology. Reactivity varied with 27% indicating answering symptom questions did not affect how they felt and 44% and 68% indicated answering questions and wearing the accelerometer, respectively, made them want to increase activity. Conclusions: Findings indicate EMA methods are feasible for breast cancer patients undergoing chemotherapy. EMA may help us better understand the biopsychosocial processes underlying breast cancer patients’ activity in the context of daily life.

KW - Breast cancer

KW - Chemotherapy

KW - Patient-reported outcomes

KW - Physical activity

KW - mHealth

UR - http://www.scopus.com/inward/record.url?scp=85073986750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073986750&partnerID=8YFLogxK

U2 - 10.1007/s11136-019-02278-7

DO - 10.1007/s11136-019-02278-7

M3 - Article

C2 - 31493269

AN - SCOPUS:85073986750

VL - 28

SP - 3333

EP - 3346

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 12

ER -